Form 8-K Fulcrum Therapeutics, For: Sep 24

Go back to Form 8-K Fulcrum Therapeutics, For: Sep 24

Fulcrum Therapeutics Inc. (FULC) will reduce its workforce

September 24, 2024 4:09 PM EDT

Fulcrum Therapeutics Inc. (NASDAQ: FULC) disclosed:

On September 24, 2024, Fulcrum announced the approval by its board of directors of a plan to reprioritize research and development activities to focus on advancing pociredir for the treatment of sickle cell disease, novel therapeutic agents for the treatment of Diamond-Blackfan anemia, and... More